TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10087435
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous heparin
Study: 29278871
Drug: Traditional dysphagia
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional dysphagia therapy (TDT) + surface neuromuscular electrical stimulation (sNMES) in treatment group A (TGA)
Study: 29278871
Drug: Traditional dysphagia
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional dysphagia therapy (TDT) + surface neuromuscular electrical stimulation (sNMES) in treatment group B (TGB)
Study: 29278871
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (traditional dysphagia therapy only)
Study: 23254482
Drug: G-Cog power
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-Cog power meter
Study: 18727842
Drug: 21 mg/24-h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21 mg/24-h nicotine patch
Study: 18727842
Drug: 15 mg/16-h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/16-h nicotine patch
Study: 8761582
Drug: 3-day Quinimax
Normalized name: quinidine sulfate Extended Release Oral Tablet [Quinidex]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day Quinimax treatment (25 mg/kg daily in 3 doses)
Study: 8761582
Drug: 7-day Quinimax
Normalized name: quinidine sulfate Extended Release Oral Tablet [Quinidex]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day Quinimax treatment (25 mg/kg daily in 3 doses)
Study: 8761582
Drug: 3-day Quinimax
Normalized name: quinidine sulfate Extended Release Oral Tablet [Quinidex]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day Quinimax treatment
Study: 2328746
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg b.d. for one week
Study: 2328746
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg b.d. for one week
Study: 28652290
Drug: Duloxetine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (30 mg for 2 weeks, then 60 mg for 4 weeks)
Study: 15113316
Drug: Gatifloxacin 400
Normalized name: gatifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gatifloxacin 400 mg once-daily for 5-14 days
Study: 15113316
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg twice-daily for 5-14 days
Study: 25322274
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg Resveratrol (RSV(high))
Study: 25322274
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg Resveratrol (RSV(low))
Study: 1589237
Drug: Aspirin (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (1200 mg in effervescent solution)
Study: 1589237
Drug: Placebo (identically
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identically tasting solution without aspirin)
Study: 12957419
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and Placebo
Study: 3755052
Drug: Cimetidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (300 mg oral dose)
Study: 27085322
Drug: Orofacial myofunctional
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orofacial myofunctional therapy (OMT) + OM exercises
Study: 23991748
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with antibiotic susceptibility testing after MALDI‐TOF MS identification
Study: 20610466
Drug: Patients' beliefs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients' beliefs about hypertension and treatment
Study: 8857989
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (15 mmol/L) in the cardioplegic solution (group 1)
Study: 8857989
Drug: No magnesium
Normalized name: DPBS 1X, NO CALCIUM, NO MAGNESIUM
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No magnesium sulfate in the cardioplegic solution (group 2)
Study: 1320540
Drug: Candoxatril (10-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candoxatril (10-200 mg)
Study: 1320540
Drug: Exogenous infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exogenous infusion of synthetic human atrial natriuretic peptide (45-90 micrograms)
Study: 6407290
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Zaditen and Intal
Study: 20444958
Drug: Iron-fortified food
Normalized name: INFANT FORMULA SMA IRON FORTIFIED CONC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-fortified food product (total dose = 56 mg Fe/d), consumed twice daily during the 9-week BCT course.
Study: 20444958
Drug: Placebo, consumed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, consumed twice daily during the 9-week BCT course.
Study: 1453197
Drug: Continuous therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous therapy
Study: 15712083
Drug: CD4 cell
Normalized name: lisocabtagene maraleucel
DrugBank: Lisocabtagene maraleucel (DB16582)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD4 cell count-guided therapy
Study: 15712083
Drug: Week-on/week-off (WOWO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Week-on/week-off (WOWO) therapy
Study: 15712083
Drug: All therapy
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All therapy arms
Study: 12001824
Drug: 1% N-acetylcarnosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% N-acetylcarnosine (NAC) solution, topical eyedrops twice daily
Study: 10424185
Drug: Polyester clothing
Normalized name: polyester-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyester clothing with low moisture absorption and low air permeability (A)
Study: 10424185
Drug: Polyester clothing
Normalized name: polyester-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyester clothing with low moisture absorption and high air permeability (B)
Study: 10424185
Drug: Cotton clothing
Normalized name: Cotton
DrugBank: Cotton (DB10707)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotton clothing with high moisture absorption and high air permeability (C)
Study: 7547617
Drug: Oral pancreatic
Normalized name: pancreatin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pancreatic enzyme supplements
Study: 2237719
Drug: Meciadanol, 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meciadanol, 500 mg every six hours through a nasogastric tube
Study: 2237719
Drug: Sucralfate, 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate, 1,000 mg every six hours through a nasogastric tube
Study: 2237719
Drug: Antacid (Maalox),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid (Maalox), 15 ml every hour through a nasogastric tube
Study: 28670677
Drug: Intraurethral lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraurethral lidocaine gel 2% plus intraglandular injection of lidocaine 2% (Group A)
Study: 28670677
Drug: Intraurethral lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraurethral lidocaine gel 2% alone (Group B)
Study: 23021709
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (RT) to the breast/chest wall and regional lymph nodes
Study: 9175687
Drug: Positive for
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive for anti-beta2GPI antibodies (group II)
Study: 9175687
Drug: Negative for
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative for both antibodies (group I)
Study: 1337164
Drug: Interferon (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon (3 x 10(6) units thrice weekly for the first 6 weeks, then twice weekly for a further 8 weeks)
Study: 3989143
Drug: Epinephrine (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine (high dose)
Study: 30180054
Drug: Local steroid
Normalized name: RECTAL,LOCAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local steroid (40 mg of local triamcinolone)
Study: 30180054
Drug: IV steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV steroid (10 mg of IV dexamethasone)
Study: 19164187
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 750 microg twice daily
Study: 16120115
Drug: Mechanical periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mechanical periodontal treatment combined with systemic doxycycline, 100 mg day(‐1) for 14 days
Study: 16120115
Drug: Neither periodontal
Normalized name: 2,2',3,3',4,4',5,5',6-nonachlorodiphenyl either
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neither periodontal treatment nor systemic doxycycline
Study: 12107836
Drug: Gemcitabine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1000 mg/m(2)) + Marimastat
Study: 12107836
Drug: Gemcitabine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1000 mg/m(2)) + Placebo
Study: 10402383
Drug: Midazolam 0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.06 mg/kg and Ketamine 0.75 mg/kg
Study: 10402383
Drug: Fentanyl 0.017
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 0.017 mg/kg, Propofol 2.5 mg/kg and Isoflurane
Study: 7530597
Drug: Bleomycin (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bleomycin (0.03 unit/ml for 5 hours)
Study: 2033221
Drug: Continuous nasogastric
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous nasogastric antacid infusion at 0.5 ml/min and i.v. injection of cimetidine 100 mg/h (treatment group)
Study: 2033221
Drug: Ranitidine 50
Normalized name: ranitidine 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 50 mg 8 hourly i.v. (control group)
Study: 7018363
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination tablet containing 5 mg of timolol, 25 mg of hydralazine, 25 mg of hydrochlorothiazide and 37.5 mg of triamterene
Study: 24051993
Drug: Conventional occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional occupational therapy alone
Study: 23292233
Drug: Selenium (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium (200 mcg twice daily)
Study: 22145499
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg parecoxib sodium injection (treatment group; n = 133)
Study: 19307511
Drug: Hormonal therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal therapy duration more than 5 years
Study: 19307511
Drug: Hormonal therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal therapy duration less than or equal to 1 year
Study: 19307511
Drug: Hormonal therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal therapy duration more than 1 year and less than or equal to 5 years
Study: 15637558
Drug: Intranasal amphotericin
Normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal amphotericin B (20 mL, 250 mug/mL, twice daily for 6 months)
Study: 15637558
Drug: Placebo (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (20 mL, twice daily for 6 months)
Study: 12464951
Drug: Intranasal amphotericin
Normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal amphotericin B
Study: 10076939
Drug: Low-dose glucocorticoid
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose glucocorticoid (prednisone at < 5 mg/day) for at least 12 months
Study: 10076939
Drug: Nonsteroidal anti‐rheumatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroidal anti‐rheumatic drugs (NSAIDs)
Study: 7720339
Drug: Brain natriuretic
Normalized name: Brain natriuretic peptide
DrugBank: .gamma.-brain natriuretic peptide (DB19026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brain natriuretic peptide infusion
Study: 1817904
Drug: Premedication with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premedication with a combination of a neuroleptic drug and an opiate or a benzodiazepine
Study: 7449717
Drug: Zopiclone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zopiclone (10 mg)
Study: 27613814
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of ropivacaine for 24 hours
Study: 27613814
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline infusion for 24 hours
Study: 25648969
Drug: Postoperative glenohumeral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative glenohumeral injection of bupivacaine (20mL) and lidocaine (10mL)
Study: 25648969
Drug: Postoperative injection
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative injection administered in the subacromial space of bupivacaine (20mL) and lidocaine (10mL)
Study: 25648969
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of glenohumeral and subacromial injections of bupivacaine (20mL) and lidocaine (10mL)
Study: 25648969
Drug: Demerol as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Demerol as a postinjection rescue analgesic
Study: 24055512
Drug: VAC therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAC therapy
Study: 19755697
Drug: Placebo metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo metformin
Study: 15300570
Drug: Enteric-coated aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated aspirin 81 mg/day
Study: 15300570
Drug: Rofecoxib 25
Normalized name: rofecoxib 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib 25 mg combined with aspirin 81 mg/day
Study: 15300570
Drug: Ibuprofen 800
Normalized name: ibuprofen 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 800 mg 3 times a day
Study: 11214056
Drug: Low-dose rhTFPI
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose rhTFPI (0.05 mg/ml)
Study: 11214056
Drug: High-dose rhTFPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose rhTFPI (0.15 mg/ml)
Study: 11214056
Drug: Heparin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (100 U/ml)
Study: 8082100
Drug: Ondansetron (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (24 mg i.v.) in Study 1
Study: 8082100
Drug: Granisetron (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron (3 mg i.v.) in Study 1
Study: 8082100
Drug: Ondansetron (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (8 mg orally twice a day) for delayed emesis in Study 1
Study: 8082100
Drug: Granisetron (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron (3 mg i.v.) for delayed emesis in Study 1
Study: 8082100
Drug: Ondansetron (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (16 mg i.v.) in Study 2
Study: 8082100
Drug: Granisetron (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron (3 mg i.v.) in Study 2
Study: 2644877
Drug: Nifedipine 20
Normalized name: nifedipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 20 mg daily
Study: 6486124
Drug: Nifedipine 40
Normalized name: nifedipine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 40 mg daily
Study: 2644877
Drug: Nifedipine (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (both doses)
Study: 1103213
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (30 to 240 mg of elemental iron as ferrous fumarate)
Study: 1103213
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (120 mg of iron without B12 or folate)
Study: 1103213
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (120 mg or more)
Study: 18095948
Drug: Program 1
Normalized name: 0.4 ML Program 100 MG/ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Program 1 (self-adjusted insulin dose)
Study: 18095948
Drug: Program 2
Normalized name: Program 205 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Program 2 (investigator-reminded insulin dose)
Study: 10230181
Drug: Stimulant medications
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulant medications
Study: 15723384
Drug: Extended-release delivery
Normalized name: tramadol
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Extended-release delivery systems
Study: 15723384
Drug: Second-line medications
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-line medications
Study: 15723384
Drug: Medication adjustment
Normalized name: DEPEND ADJUSTABLE,MAXIMUM SM/MED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication adjustment
Study: 12230618
Drug: 3-month course
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-month course of a gonadotrophin-releasing hormone analogue before surgery
Study: 7808649
Drug: Ketorolac 30
Normalized name: ketorolac 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 30 mg suppositories
Study: 7808649
Drug: Ketorolac 10
Normalized name: ketorolac 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 10 mg suppositories
Study: 2574192
Drug: Trihexyphenidyl hydrochloride
Normalized name: Trihexyphenidyl Hydrochloride
DrugBank: Trihexyphenidyl (DB00376)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trihexyphenidyl hydrochloride (HCl), 4 mg dose
Study: 4601508
Drug: Prophylactic dose
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic dose of 0.25 g
Study: 4601508
Drug: Prophylactic dose
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic dose of 1 g
Study: 4601508
Drug: Prophylactic dose
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic dose of 2 g
Study: 4601508
Drug: Therapeutic dose
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic dose of 4 g on the first day of illness
Study: 4601508
Drug: Therapeutic dose
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic dose of 8 g on the first day of illness
Study: 4601508
Drug: Combination regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination regimen (1 g daily and 4 g on the first day of illness)
Study: 30572875
Drug: Biological disease-modifying-antirheumatic-drug
Normalized name: Quinolines, antirheumatic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological disease-modifying-antirheumatic-drug (DMARD) strategy
Study: 26317483
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A palmitate eye gel 0.1%
Study: 26317483
Drug: Carbomer eye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbomer eye gel 0.2%
Study: 26317483
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional application of vitamin A palmitate or carbomer gel
Study: 25270629
Drug: Cutamesine 1
Normalized name: Cutamesine
DrugBank: Cutamesine (DB06618)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cutamesine 1 mg/d
Study: 25270629
Drug: Cutamesine 3
Normalized name: Cutamesine
DrugBank: Cutamesine (DB06618)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cutamesine 3 mg/d
Study: 21038648
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine intestine adjusting therapy (IAT) with electro-acupuncturing and retention enema
Study: 21038648
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine intestine adjusting therapy (IAT)
Study: 21038648
Drug: Conventional drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional drug therapy and bi-level positive airway pressure ventilation
Study: 11581481
Drug: 30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg acetaminophen loading dose
Study: 11581481
Drug: 15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg acetaminophen maintenance dose
Study: 7978097
Drug: Nicotine dependence
Normalized name: Drugs used in nicotine dependence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine dependence treatment (consultation, 10 intervention sessions, structured relapse prevention program)
Study: 7978097
Drug: Nicotine dependence
Normalized name: Drugs used in nicotine dependence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine dependence treatment
Study: 31671276
Drug: EPA+DHA supplementation
Normalized name: eicosapentaenoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA+DHA supplementation (600 mg EPA and 260 mg DHA per day for 8 weeks)
Study: 31671276
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (matching capsules for the same duration of time)
Study: 27441600
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (6 g/day; 5:1 EPA:DHA)
Study: 27441600
Drug: Placebo (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (6 g/day corn/soy oil)
Study: 25871304
Drug: Best medical/surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best medical/surgical management plus daily supplementation of vitamin B6, vitamin B12, and folic acid
Study: 23698211
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin injection (B)